BVF INC/IL
CIK 1056807 · View on SEC EDGAR ↗
- Portfolio value
- $3.9B
- Positions
- 44
- As of
- June 30, 2026
#950 of 9,443 by 13F value · top 10.1%
Portfolio value QoQ: +24.6% 13F does not disclose cash
- Top 10 holdings weight
- 65.59%
- Top 25 holdings weight
- 92.49%
- Positions above 1%
- 24
- Effective number of positions
- 16.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 10.24% Est. buys $360,794,624 · sells $421,105,332
Median holding: 4.0 quarters Tracked Q4 2024–Q2 2026 · 56.4% still held
- New positions
- 7
- Increased
- 6
- Decreased
- 8
- Closed
- 4
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +50.7% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.6% · Options excluded: 0.0%
Sector breakdown
Healthcare
99.6%
Other/Unmapped
0.4%
Full portfolio 44 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. - Common Stock | $555,315,165 | 14.20% | 2,965,160 | $277,493,115 | Up ×1 | ||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $444,008,203 | 11.35% | 3,872,052 | $-14,312,513 | Down ×1 | ||
| XOMA XOMA Royalty Corporation - Common Stock | $322,715,378 | 8.25% | 7,593,303 | $241,457,573 | Up ×1 | ||
| MLTX MoonLake Immunotherapeutics - Class A Ordinary Shares | $311,544,999 | 7.97% | 16,001,284 | $13,281,065 | |||
| GHRS GH Research PLC - Ordinary Shares | $232,516,247 | 5.95% | 8,650,158 | $110,895,026 | |||
| GPCR Structure Therapeutics Inc. - American Depositary Shares | $180,697,390 | 4.62% | 3,366,823 | $13,956,334 | Down ×2 | ||
| NKTR Nektar Therapeutics - Common Stock | $166,920,946 | 4.27% | 2,391,075 | $-17,241,914 | Down ×1 | ||
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $123,629,081 | 3.16% | 1,056,027 | $-22,767,999 | Down ×1 | ||
| XNCR Xencor, Inc. - Common Stock | $114,852,892 | 2.94% | 7,133,720 | $28,820,229 | |||
| ALKS Alkermes plc - Ordinary Shares | $112,895,716 | 2.89% | 2,154,704 | $42,175,716 | Up ×1 | ||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $107,953,441 | 2.76% | 4,460,886 | $34,571,866 | |||
| CGEM Cullinan Therapeutics, Inc. - Common Stock | $104,719,937 | 2.68% | 5,750,683 | $23,002,732 | |||
| PVLA Palvella Therapeutics, Inc. - Common Stock | $102,815,615 | 2.63% | 672,789 | $-16,971,664 | Down ×1 | ||
| ZYME Zymeworks Inc. - Common Stock | $95,388,572 | 2.44% | 3,649,142 | $1,885,656 | Down ×2 | ||
| KURA Kura Oncology, Inc. - Common Stock | $92,650,086 | 2.37% | 8,445,769 | $23,985,984 | |||
| IRON Disc Medicine, Inc. - Common Stock | $84,375,182 | 2.16% | 1,153,612 | $3,023,553 | Down ×1 | ||
| STOK Stoke Therapeutics, Inc. - Common Stock | $83,356,065 | 2.13% | 2,547,557 | $407,609 | |||
| OLMA Olema Pharmaceuticals, Inc. - Common Stock | $66,251,621 | 1.69% | 5,295,893 | $-12,710,144 | |||
| ANNX Annexon, Inc. - common stock | $49,666,568 | 1.27% | 8,698,173 | $1,478,690 | |||
| CBIO Crescent Biopharma, Inc. - Common Stock | $49,477,734 | 1.27% | 2,748,763 | $-1,017,042 | |||
| ACIU AC Immune SA - Common Stock | $47,177,398 | 1.21% | 19,822,436 | $-7,334,301 | |||
| TYRA Tyra Biosciences, Inc. - Common Stock | $47,149,700 | 1.21% | 1,476,196 | $-28,538,607 | Down ×4 | ||
| STRO Sutro Biopharma, Inc. - Common Stock | $41,559,362 | 1.06% | 1,251,788 | $10,377,323 | |||
| IMCR Immunocore Holdings plc - American Depositary Shares | $41,099,200 | 1.05% | 1,294,463 | $2,071,141 | |||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $38,356,072 | 0.98% | 2,075,545 | $13,977,696 | Up ×4 | ||
| FDMT 4D Molecular Therapeutics, Inc. - Common Stock | $38,294,544 | 0.98% | 2,879,289 | $11,488,363 | |||
| QTTB Q32 Bio Inc. - Common Stock | $29,939,000 | 0.77% | 2,350,000 | Up ×1 | |||
| AVR Anteris Technologies Global Corp. - Common Stock | $29,550,000 | 0.76% | 3,000,000 | $12,900,000 | |||
| FHTX Foghorn Therapeutics Inc. - Common Stock | $28,508,960 | 0.73% | 5,842,000 | $584,200 | |||
| ABSI Absci Corporation - Common Stock | $27,371,802 | 0.70% | 2,361,674 | Up ×1 | |||
| ELDN Eledon Pharmaceuticals, Inc. - Common Stock | $24,795,531 | 0.63% | 6,293,282 | $5,412,222 | |||
| IVVD Invivyd, Inc. - Common Stock | $24,571,146 | 0.63% | 28,165,000 | $-811,354 | Up ×1 | ||
| SGMT Sagimet Biosciences Inc. - Series A Common Stock | $19,325,000 | 0.49% | 2,500,000 | Up ×1 | |||
| OKUR OnKure Therapeutics, Inc. - Class A Common Stock | $14,755,148 | 0.38% | 3,235,778 | $6,562,204 | Up ×1 | ||
| Unknown issuer (CUSIP: 4525EP200) | $11,762,584 | 0.30% | 765,295 | Up ×1 | |||
| XFOR X4 Pharmaceuticals, Inc. - Common Stock | $10,431,575 | 0.27% | 2,233,742 | $1,206,221 | |||
| IMA ImageneBio, Inc. - Common Stock | $6,549,012 | 0.17% | 1,110,002 | $999,002 | |||
| TCRX TScan Therapeutics, Inc. - Common Stock | $5,453,561 | 0.14% | 5,564,290 | $-166,372 | |||
| Unknown issuer (CUSIP: G75226103) | $5,350,000 | 0.14% | 500,000 | Up ×1 | |||
| MOLN Molecular Partners AG - American Depositary Shares | $5,145,078 | 0.13% | 1,353,968 | $-216,635 | |||
| TENX Tenax Therapeutics, Inc. - Common Stock | $4,940,438 | 0.13% | 339,549 | $-488,951 | |||
| ENTX Entera Bio Ltd. - Ordinary Shares | $4,292,250 | 0.11% | 2,425,000 | Up ×1 | |||
| IVA Inventiva S.A. - American Depository Shares | $2,593,231 | 0.07% | 686,040 | $-1,214,291 | |||
| Unknown issuer (CUSIP: 29286X119) | $274,072 | 0.01% | 945,402 | Up ×1 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
| Security | Value | % of portfolio | Streak |
|---|---|---|---|
| AVTX | $38,356,072 | 0.98% | up ×4 |
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| QTTB | $29,939,000 | 2,350,000 | 0.77% |
| ABSI | $27,371,802 | 2,361,674 | 0.70% |
| SGMT | $19,325,000 | 2,500,000 | 0.49% |
| Unknown issuer (CUSIP: 4525EP200) | $11,762,584 | 765,295 | 0.30% |
| Unknown issuer (CUSIP: G75226103) | $5,350,000 | 500,000 | 0.14% |
| ENTX | $4,292,250 | 2,425,000 | 0.11% |
| Unknown issuer (CUSIP: 29286X119) | $274,072 | 945,402 | 0.01% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| RVMD | Bought more | +108K | +$277.5M |
| XOMA | Bought more | +5.0M | +$241.5M |
| GHRS | Price move only | +0 | +$110.9M |
| ALKS | Bought more | +155K | +$42.2M |
| GLUE | Price move only | +0 | +$34.6M |
| XNCR | Price move only | +0 | +$28.8M |
| TYRA | Trimmed | -500K | -$28.5M |
| KURA | Price move only | +0 | +$24.0M |
| CGEM | Price move only | +0 | +$23.0M |
| MIRM | Trimmed | -529K | -$22.8M |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| PTGX | Dec. 31, 2025 | 2,560,916 | $170,121,650 | 80.5% |
| CDTX | Dec. 31, 2025 | 1,414,165 | $135,420,440 | No longer tracked |
| IONS | Sept. 30, 2025 | 1,913,385 | $75,597,841 | -7.8% |
| ABVX | March 31, 2026 | 508,031 | $68,510,521 | 7.8% |
| CMPX | June 30, 2026 | 7,764,842 | $41,076,014 | 13.5% |
| GLPG | June 30, 2025 | 1,454,422 | $36,535,081 | No longer tracked |
| AGIO | March 31, 2025 | 1,073,755 | $35,283,589 | 20.9% |
| ETNB | March 31, 2025 | 4,333,885 | $33,890,981 | No longer tracked |
| CELC | Dec. 31, 2025 | 658,421 | $32,525,997 | -4.9% |
| SEPN | June 30, 2026 | 1,353,249 | $32,518,573 | 31.4% |
| VERV | June 30, 2025 | 6,904,050 | $31,551,509 | No longer tracked |
| RPTX | March 31, 2026 | 10,333,600 | $26,867,360 | No longer tracked |
| ITOS | June 30, 2025 | 3,075,000 | $18,357,750 | No longer tracked |
| VSTM | Sept. 30, 2025 | 3,404,425 | $14,128,364 | -14.9% |
| ENGN | March 31, 2025 | 2,106,037 | $14,005,146 | -60.9% |
| PEPG | March 31, 2026 | 1,915,000 | $12,466,650 | 63.8% |
| RAPT | Sept. 30, 2025 | 1,154,692 | $9,237,536 | No longer tracked |
| IMUX | June 30, 2026 | 7,652,972 | $8,494,799 | 10.8% |
| AXSM | March 31, 2026 | 45,757 | $8,357,058 | 30.4% |
| THRD | June 30, 2025 | 2,372,933 | $8,234,078 | No longer tracked |
| VIGL | June 30, 2025 | 4,013,633 | $7,144,267 | No longer tracked |
| IKNA | Sept. 30, 2025 | 4,006,564 | $5,368,796 | No longer tracked |
| ALLK | June 30, 2025 | 16,552,417 | $3,767,330 | No longer tracked |
| CTMX | June 30, 2025 | 5,228,461 | $3,324,256 | 55.1% |
| ENGNW | June 30, 2026 | 945,402 | $2,486,407 | -89.0% |
| EPIX | Dec. 31, 2025 | 11,668,473 | $2,228,678 | No longer tracked |
| GLYC | June 30, 2025 | 9,544,262 | $2,004,295 | No longer tracked |
| SABS | Dec. 31, 2025 | 932,697 | $1,874,721 | 2.9% |
| ELEV | March 31, 2025 | 2,966,836 | $1,669,142 | No longer tracked |
| OVID | Sept. 30, 2025 | 3,853,818 | $1,271,375 | 122.7% |
| NAMS | June 30, 2025 | 59,065 | $1,209,061 | 53.6% |
| FBRX | Dec. 31, 2025 | 65,350 | $980,250 | 182.1% |
| NLSP | Dec. 31, 2025 | 143,676 | $262,927 | No longer tracked |